Company Filing History:

10 out of 1,001

Shionogi Company Limited

patents

9 out of 40

Viiv Healthcare Company

where one patent can have more than one assignee

Years Active: 2012-2017

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9707246 - Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents (2017-07-18),

2. 9133216 - (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10 (2015-09-15),

3. 9012650 - Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents (2015-04-21),

4. 8981129 - 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4 (2015-03-17),

5. 8940912 - 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid (2015-01-27),

6. 8765965 - 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7 (2014-07-01),

7. 8669362 - Processes and Intermediates for carbamoylpyridone HIV integrase inhibitors (2014-03-11),

8. 8580967 - Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof (2013-11-12),

9. 8552187 - Processes and intermediates for carbamoylpyridone HIV integrase inhibitors (2013-10-08),

10. 8217034 - Chemical compounds (2012-07-10),

Title: The Innovative Contributions of Toshikazu Hakogi

Introduction

Toshikazu Hakogi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating viral infections, including HIV. With a total of 10 patents to his name, Hakogi's work reflects a commitment to advancing healthcare through innovative solutions.

Latest Patents

Hakogi's latest patents include a series of compounds designed as HIV agents. One notable invention is the substituted (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides. This invention outlines a method for treating viral infections, particularly HIV, by administering specific compounds that have shown potential in combating the virus. Another significant patent involves intermediates in the preparation of therapeutic agents, specifically (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione and its derivatives.

Career Highlights

Throughout his career, Hakogi has worked with notable companies such as Shionogi & Company Limited and ViiV Healthcare. His experience in these organizations has allowed him to collaborate on various projects aimed at developing effective treatments for viral infections. His dedication to research and innovation has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Hakogi has collaborated with several professionals in his field, including Brian Alvin Johns and Jason Gordon Weatherhead. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Toshikazu Hakogi's contributions to medicinal chemistry and his innovative patents highlight his commitment to improving healthcare outcomes. His work in developing treatments for viral infections, particularly HIV, showcases the importance of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com